For many emerging biotechnology companies, customs classification is often treated as an administrative task, handed to a customs broker shortly before a shipment leaves a manufacturing site. In reality, tariff classification decisions can significantly affect cash flow, duty exposure, customs audits, clinical trial timelines, and overall supply chain risk.
As development-stage biotechs rely more on global manufacturing networks, importing investigational medicinal products (IMPs), active pharmaceutical ingredients (APIs), comparators, placebos, and clinical trial materials has become a routine part of business operations. Yet few small companies have dedicated trade compliance expertise. As a result, tariff classifications are often inherited from suppliers, copied from prior entries, or chosen without a full understanding of how the Harmonized Tariff Schedule of the United States (HTSUS) works.
This approach can create substantial risk. According to U.S. Customs and Border Protection (CBP), importers are responsible for exercising reasonable care when classifying imported merchandise and for providing the information customs authorities need to properly assess duties and enforce applicable laws.
For small biotech companies operating with limited resources, successful customs compliance is therefore not about finding the tariff code with the lowest duty rate.





